GlassScriptPhysician profile
Parth Desai
NPI 1184074171
$4,578.13
in general payments reported to CMS, 2019-2025
9 companies · $4,208 in 2025
The $4,208 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $264 · 2024: $106 · 2025: $4,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,855 · Honoraria: $1,755 · Food and Beverage: $574 · Travel and Lodging: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,855.00 |
| Honoraria | $1,755.00 |
| Food and Beverage | $573.67 |
| Travel and Lodging | $394.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $2,282.11 | 2025 | Gavreto |
| Merck Sharp & Dohme LLC | $1,855.00 | 2025 | |
| Abbott Laboratories | $136.83 | 2023 | Mitraclip, Amplatzer |
| Boston Scientific Corporation | $101.77 | 2023 | Acquire |
| Janssen Biotech, INC. | $86.98 | 2024 | Rybrevant |
| Daiichi Sankyo INC. | $43.93 | 2025 | |
| Caris Mpi, INC. | $27.07 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $25.54 | 2023 | Zepzelca |
| Ardelyx, INC. | $18.90 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parth Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.